NLRP5

Across TCGA pan-cancer cohorts, NLRP5 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated NLRP5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher NLRP5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NLRP5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, THYM, and SARC are the cancer types where NLRP5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	II,III,IV	0.016	0.406	<.001	33	view →
THYM	OS	Median	All	0.068	0.977	<.001	24	view →
SARC	OS	Median	All	0.214	0.749	<.001	15	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
READ	OS	Median	II,III,IV	0.287	0.829	.008	11	view →
LGG	DFS	Median	All	0.350	0.741	.015	9	view →
UCEC	DFS	Median	All	0.893	0.612	.012	8	view →
ACC	OS	Median	All	0.149	0.686	.047	3	view →
ESCA	OS	Median	All	0.412	0.704	.008	3	view →
COAD	OS	Median	IV	0.196	0.669	.016	3	view →
SKCM	DFS	Median	III,IV	0.310	0.685	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

NLRP5–CHOL (DFS)

Open the CHOL breakdown →